RWM
KRYS icon

Rialto Wealth Management’s Krystal Biotech KRYS Stock Holding History

Rialto Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$259 Hold
1
– – ﹤0.01% 1564
2025
Q4 		$247 Buy
+1
New +$210 ﹤0.01% 1469

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rialto Wealth Management's KRYS Position: Q1 2026 in Review

Rialto Wealth Management held its Krystal Biotech (KRYS) position steady in Q1 2026 at 1 share worth $259. The position accounts for ﹤0.01% of the portfolio, ranked #1564.

Rialto Wealth Management first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Rialto Wealth Management held 1 share of Krystal Biotech worth $259 as of Q1 2026.
  • Rialto Wealth Management left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1564 holding.
  • Rialto Wealth Management first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.